enzalutamide + androgen deprivation therapy

Enzalutamide + androgen deprivation therapy is a drug combination used primarily for the treatment of advanced and metastatic prostate cancer. Enzalutamide is a potent, second-generation androgen receptor inhibitor that competitively inhibits androgen binding, blocks receptor nuclear translocation, and prevents DNA-mediated oncogene activation. Androgen deprivation therapy (ADT) refers to interventions for suppressing or eliminating circulating androgens, typically through surgical or medical castration (e.g., GnRH agonists/antagonists, or orchiectomy). This combination effectively inhibits androgen receptor signaling, suppresses testosterone-driven tumor progression, and significantly reduces the risk of radiographic progression and mortality in men with hormone-sensitive or castration-resistant prostate cancer[1][2][3][4][6][7].

Brand names

Xtandi

Other names

enzalutamide plus androgen deprivation therapyenzalutamide + ADTenzalutamide plus ADT